USD 18.51
(5.05%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -3.36 Million USD | -143.07% |
2022 | -1.38 Million USD | -100.37% |
2021 | 370.84 Million USD | 515162.5% |
2020 | -72 Thousand USD | 0.0% |
2019 | - USD | 0.0% |
2017 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -977 Thousand USD | -3.83% |
2024 Q1 | -941 Thousand USD | 0.74% |
2023 Q2 | -800 Thousand USD | -4.71% |
2023 FY | -3.36 Million USD | -143.07% |
2023 Q1 | -764 Thousand USD | 99.7% |
2023 Q3 | -857 Thousand USD | -7.13% |
2023 Q4 | -948 Thousand USD | -10.62% |
2022 Q1 | 292.51 Million USD | 89.86% |
2022 FY | -1.38 Million USD | -100.37% |
2022 Q4 | -250.82 Million USD | -66430.5% |
2022 Q3 | -377 Thousand USD | -100.18% |
2022 Q2 | 214.62 Million USD | -26.63% |
2021 Q4 | 154.06 Million USD | 39.77% |
2021 Q1 | 30.96 Million USD | 0.0% |
2021 Q2 | 75.59 Million USD | 144.16% |
2021 Q3 | 110.22 Million USD | 45.81% |
2021 FY | 370.84 Million USD | 515162.5% |
2020 Q2 | 6.64 Million USD | 813.34% |
2020 FY | -72 Thousand USD | 0.0% |
2020 Q3 | 13.42 Million USD | 102.11% |
2020 Q1 | 727 Thousand USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
ADC Therapeutics SA | 67.02 Million USD | 105.026% |
Alto Neuroscience, Inc. | -373 Thousand USD | -803.217% |
Annovis Bio, Inc. | - USD | Infinity% |
Ginkgo Bioworks Holdings, Inc. | 197.45 Million USD | 101.706% |
Nuvation Bio Inc. | -222 Thousand USD | -1417.568% |
Nuvation Bio Inc. | -222 Thousand USD | -1417.568% |
Arcus Biosciences, Inc. | -223 Million USD | 98.489% |
Zymeworks Inc. | -66.97 Million USD | 94.97% |